Systemic combined treatment of MDSCs and Treg cells improved clinical GVHD severity, effectively modulating the T helper cell response, reduced the percentage of alloreactive of Th1, and Th17 cells, and increased the frequencies of Th2 and Foxp3 + Treg cells. The gene discussed is FOXP3; the disease is graft versus host disease.